Who owns Cytomx Therapeutics?
- Ticker: CTMX
- CUSIP Number: 23284f105
Tip: Access positions for across all investors
Analyze quarterly positions in Cytomx Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Cytomx Therapeutics stock
Who bought or sold Cytomx Therapeutics this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| BVF | 6.6M | $14M | 0% | Mar 2024 |
|
| Tang Capital Management | 6.5M | $14M | -2% | Mar 2024 |
|
| Vanguard Group | 4.9M | $11M | -1% | Mar 2024 |
|
| OrbiMed Advisors | 3.5M | $7.7M | 100% | Mar 2024 |
|
| Acadian Asset Management | 2.7M | $5.9M | 2% | Mar 2024 |
|
| Adage Capital Partners GP | 2.0M | $4.4M | 100% | Mar 2024 |
|
| Sio Capital Management | 1.6M | $3.5M | 100% | Mar 2024 |
|
| Schonfeld Strategic Advisors | 1.3M | $2.8M | 100% | Mar 2024 |
|
| BlackRock | 1.1M | $2.5M | -1% | Mar 2024 |
|
| Susquehanna International | 986k | $2.1M | 1013% | Mar 2024 |
|
| Bronte Capital Management Pty | 906k | $2.0M | -1% | Mar 2024 |
|
| Morgan Stanley | 856k | $1.9M | 1245% | Mar 2024 |
|
| Laurion Capital Management | 764k | $1.7M | -30% | Mar 2024 |
|
| Geode Capital Management | 753k | $1.6M | 11% | Mar 2024 |
|
| Superstring Capital Management | 679k | $1.5M | 100% | Mar 2024 |
|
| Millennium Management | 672k | $1.5M | -15% | Mar 2024 |
|
| Jacobs Levy Equity Management | 530k | $1.2M | -33% | Mar 2024 |
|
| Bridgeway Capital Management | 443k | $966k | 19% | Mar 2024 |
|
| Assenagon Asset Management | 405k | $882k | 0% | Mar 2024 |
|
| Connor, Clark & Lunn Investment Management | 304k | $663k | 55% | Mar 2024 |
|
| Goldman Sachs Group | 294k | $641k | 100% | Mar 2024 |
|
| BBK Capital Partners | 288k | $628k | -6% | Mar 2024 |
|
| Toroso Investments | 288k | $631k | -6% | Mar 2024 |
|
| Squarepoint Ops | 257k | $561k | 71% | Mar 2024 |
|
| Two Sigma Investments | 254k | $553k | 1695% | Mar 2024 |
|
| Bank of New York Mellon | 242k | $528k | -9% | Mar 2024 |
|
| Congress Park Capital | 234k | $510k | -2% | Mar 2024 |
|
| Clearline Capital | 197k | $429k | 0% | Mar 2024 |
|
| Man Group | 191k | $417k | 100% | Mar 2024 |
|
| Jane Street | 184k | $401k | 528% | Mar 2024 |
|
| FMR | 183k | $399k | -74% | Mar 2024 |
|
| ADAR1 Capital Management | 155k | $338k | 100% | Mar 2024 |
|
| GSA Capital Partners | 149k | $324k | 43% | Mar 2024 |
|
| Two Sigma Advisers | 147k | $320k | 256% | Mar 2024 |
|
| Northern Trust | 134k | $292k | 12% | Mar 2024 |
|
| Qube Research & Technologies | 133k | $290k | 51328% | Mar 2024 |
|
| Citigroup | 124k | $270k | 100% | Mar 2024 |
|
| Bank Of Montreal | 108k | $238k | 51% | Mar 2024 |
|
| LPL Financial | 92k | $201k | -12% | Mar 2024 |
|
| Point72 Asia | 87k | $190k | 100% | Mar 2024 |
|
| Walleye Trading Advisors | 86k | $187k | 100% | Mar 2024 |
|
| CornerCap Investment Counsel | 81k | $177k | 0% | Mar 2024 |
|
| Bank of America Corporation | 78k | $170k | 338% | Mar 2024 |
|
| Private Advisor | 69k | $151k | -5% | Mar 2024 |
|
| Susquehanna Fundamental Investments | 57k | $124k | 100% | Mar 2024 |
|
| Y-Intercept | 56k | $121k | 100% | Mar 2024 |
|
| Commonwealth Equity Services | 53k | $116k | 0% | Mar 2024 |
|
| Marshall Wace | 52k | $114k | -86% | Mar 2024 |
|
| Citadel Advisors | 50k | $109k | -82% | Mar 2024 |
|
| Tudor Investment Corporation | 44k | $96k | -2% | Mar 2024 |
|
| Russell Investments | 43k | $93k | 3% | Mar 2024 |
|
| Cubist Systematic Strategies | 42k | $91k | 100% | Mar 2024 |
|
| Balyasny Asset Management | 32k | $70k | 100% | Mar 2024 |
|
| SG Americas Securities | 26k | $57k | 100% | Mar 2024 |
|
| Charles Schwab Investment Management | 25k | $54k | 0% | Mar 2024 |
|
| Forefront Analytics | 21k | $46k | -58% | Mar 2024 |
|
| UBS Group | 21k | $45k | 2% | Mar 2024 |
|
| CTC Alternative Strategies | 19k | $41k | 100% | Mar 2024 |
|
| LMR Partners | 18k | $40k | 100% | Mar 2024 |
|
| Mackenzie Financial | 18k | $40k | -8% | Mar 2024 |
|
| Brevan Howard Capital Management | 18k | $39k | 100% | Mar 2024 |
|
| Taddei, Ludwig & Associates | 17k | $37k | 0% | Mar 2024 |
|
| Hrt Financial | 17k | $36k | 100% | Mar 2024 |
|
| XTX Topco | 13k | $27k | 100% | Mar 2024 |
|
| IPG Investment Advisors | 13k | $19k | 100% | Dec 2023 |
|
| ExodusPoint Capital Management | 11k | $24k | 100% | Mar 2024 |
|
| D. E. Shaw & Co | 11k | $24k | -7% | Mar 2024 |
|
| Vontobel Holding | 10k | $22k | 0% | Mar 2024 |
|
| Whittier Trust | 6.6k | $14k | 0% | Mar 2024 |
|
| Simplex Trading | 6.1k | $13k | 100% | Mar 2024 |
|
| Federated Investors | 3.5k | $5.4k | 146% | Dec 2023 |
|
| Rhumbline Advisers | 1.3k | $2.8k | 0% | Mar 2024 |
|
| Lazard Asset Management | 1.3k | $1.0k | 100% | Dec 2023 |
|
| Bollard | 712.00 | $2.0k | 0% | Mar 2024 |
|
| Group One Trading | 637.00 | $1.4k | 0% | Mar 2024 |
|
| Wells Fargo & Company | 524.00 | $1.1k | 2% | Mar 2024 |
|
| Jpmorgan Chase & Co | 281.00 | $613.001500 | 0% | Mar 2024 |
|
| Raleigh Capital Management | 250.00 | $545.000000 | 0% | Mar 2024 |
|
| Old Point Trust & Financial Services N A | 250.00 | $545.000000 | 100% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 78.00 | $170.001000 | 0% | Mar 2024 |
|
Who sold out of Cytomx Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Franklin Resources | Dec 2023 | 27k | $42k |
| AlphaMark Advisors | Dec 2023 | 23k | $36k |
| Tower Research Capital | Sep 2023 | 8.2k | $11k |
| Byrne Asset Management | Dec 2023 | 8.0k | $12k |
| Cutler | Dec 2023 | 1.0k | $1.0k |
| Royal Bank of Canada | Dec 2023 | 798.00 | $1.6k |
| Advisory Services Network | Dec 2023 | 274.00 | $425.001400 |